Anti‐PD ‐1 therapy can possibly reverse CAR T cells exhaustion in DLBCL
British Journal of Haematology · 2023-07 · 202 (2) · 217-218
DOI: 10.1111/bjh.18797 ↗Kurz gefasst
Kommentar in der Zeitschrift British Journal of Haematology, online erschienen am 04.04.2023. Verfasst von Sylvain Lamure und 1 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Hématologie Clinique, CHU de Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: T-Lymphocytes, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Département d'Hématologie Clinique, CHU de Montpellier, Montpellier, France.
- Hematopoiesis and Immunotherapy, Institut de Génétique Moléculaire de Montpellier, Université de Montpellier, Montpellier, France.
- Laboratory for monitoring Innovative Therapies, Institut de Génétique Humaine, Université de Montpellier, Montpellier, France.
ORCID-Profile: Charles Herbaux
Zitieren
APA
Lamure, S., & Herbaux, C. (2023). Anti‐PD ‐1 therapy can possibly reverse CAR T cells exhaustion in DLBCL. British Journal of Haematology, 202(2), 217-218. https://doi.org/10.1111/bjh.18797
Vancouver
Lamure S, Herbaux C. Anti‐PD ‐1 therapy can possibly reverse CAR T cells exhaustion in DLBCL. British Journal of Haematology. 2023;202(2):217-218. doi:10.1111/bjh.18797
BibTeX
@article{Lamure2023,
author = {Lamure, Sylvain and Herbaux, Charles},
title = {Anti‐PD ‐1 therapy can possibly reverse CAR T cells exhaustion in DLBCL},
journal = {British Journal of Haematology},
year = {2023},
volume = {202},
number = {2},
pages = {217--218},
doi = {10.1111/bjh.18797}
}
EUVIMED